Results 81 to 90 of about 1,844 (180)

Myosin Modulator Aficamten Inhibits Force by Altering Myosin’s Biochemical Activity Without Changing Thick Filament Structure

JACC: Basic to Translational Science
Summary: We investigated the effects of aficamten on cardiac muscle structure, biochemical activity, and contractile function. Aficamten does not structurally sequester myosin heads along the thick filament.
Saffie Mohran, PhD, Kristina B. Kooiker, PhD, Ateeqa Naim, BS, Matvey Pilagov, BS, Anthony Asencio, BS, Kyrah L. Turner, BS, Weikang Ma, PhD, Galina Flint, MD., Siyao Jiang, BS, Jing Zhao, BS, Timothy S. McMillen, PhD, Christian Mandrycky, PhD, Max Mahoney-Schaefer, BS, Thomas C. Irving, PhD, Bertrand C.W. Tanner, PhD, Neil M. Kad, PhD, Michael Regnier, PhD, Farid Moussavi-Harami, MD   +17 more
doaj   +1 more source

Diagnosis and Treatment of Obstructive Hypertrophic Cardiomyopathy [PDF]

, 2023
Left ventricular outflow obstruction (LVOTO) and diastolic dysfunction are the main pathophysiological characteristics of hypertrophic cardiomyopathy (HCM)LVOTO, may be identified in more than half of HCM patients and represents an important determinant ...
Errico Federico Perillo, Felice Borrelli, Gaetano Todde, Giovanni Esposito, Grazia Canciello, Maria Angela Losi Maria Angela Losi, Raffaella Lombardi   +6 more
core  

Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction

Nature Communications
Inherited cardiomyopathies are common cardiac diseases worldwide, leading in the late stage to heart failure and death. The most promising treatments against these diseases are small molecules directly modulating the force produced by β-cardiac myosin ...
Daniel Auguin, Julien Robert-Paganin, Stéphane Réty, Carlos Kikuti, Amandine David, Gabriele Theumer, Arndt W. Schmidt, Hans-Joachim Knölker, Anne Houdusse   +8 more
doaj   +1 more source

Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology

Biomedicines
Hypertrophic cardiomyopathy (HCM) is a heterogeneous group of heart muscle disorders that affects millions, with an incidence from 1 in 500 to 1 in 200. Factors such as genetics, age, gender, comorbidities, and environmental factors may contribute to the
Ewelina Młynarska, Ewa Radzioch, Bartłomiej Dąbek, Klaudia Leszto, Alicja Witkowska, Witold Czarnik, Weronika Jędraszak, Jacek Rysz, Beata Franczyk   +8 more
doaj   +1 more source

The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients, a systematic review and meta-analysis

Indian Heart Journal
Background: Evaluate the effect of mavacamten on echocardiographic parameters and cardiac biomarkers in patients with hypertrophic cardiomyopathy (HCM).
Zina Otmani, Noura Abdrabou, Hazem Ayman Elsayed, Mazen Negmeldin Aly Yassin, Mohamed Abouzid, Mahmoud Diaa Hindawi, Ayman K. Awad   +6 more
doaj   +1 more source

Myosin inhibitors for treatment of hypertrophic cardiomyopathy [PDF]

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:/ / Primary objective: To assess the effects of myosin inhibitors compared to usual care or placebo on exercise capacity, need for septal reduction ...
Amin, Ahmad S, Asselbergs, Folkert W, Bezzina, Connie, Elliott, Perry M, Quill, Samuel, Schmidt, Amand F, van der Velden, Jolanda   +6 more
core  

Efficacy and safety of Mavacamten for symptomatic Hypertrophic cardiomyopathy – an updated Meta-Analysis of randomized controlled trials

International Journal of Cardiology: Heart & Vasculature
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder with risk of sudden cardiac death (SCD) in children and adolescents. Mavacamten, also referred to as MYK-461, a myosin inhibitor of cardiac myocytes is studied in symptomatic HCM.
Irfan Ullah, Syeda Tayyaba Rehan, Zayeema Khan, Syed Hasan Shuja, Muhammad Hamza Shuja, Muhammad Irfan, Karthik Gonuguntla, M Chadi Alraies, Pratik Aggarwal, Sameer Raina, Yasar Sattar, Muhammad Sohaib Asghar   +11 more
doaj   +1 more source

Mavacamten depresses human atrial contractility in the same EC50% range as human ventricle [PDF]

, 2022
Coppini, Raffaele, Ferrantini, Cecilia, Pioner, Jose' Manuel, Piroddi, Nicoletta, Poggesi, Corrado, Querceto, Silvia, Scellini, Beatrice, Tesi, Chiara, Vitale, Giulia   +8 more
core   +1 more source

Mavacamten

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy [PDF]

Hypertrophic cardiomyopathy (HCM) affects individuals worldwide with an estimated prevalence of over 1 in 500 individuals. Nonobstructive HCM accounts for approximately 30% to 70% of cases, is extremely heterogeneous, and is associated with a notable ...
Biagini, Elena, Charron, Philippe, Desai, Milind Y., Elliott, Perry, Fernandes, Fabio, Gonzalez-Lopez, Esther, Haelst, Paul L. van, Haugaa, Kristina Hermann, Kramer, Christopher M., Maurizi, Niccolo, Meder, Benjamin, Michels, Michelle, Owens, Anjali, Yuasa, Shinsuke   +13 more
core   +2 more sources